Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Operating Leases: 2019-2025

Historic Operating Leases for Abeona Therapeutics (ABEO) over the last 6 years, with Sep 2025 value amounting to $4.3 million.

  • Abeona Therapeutics' Operating Leases rose 25.04% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 25.04%. This contributed to the annual value of $3.3 million for FY2024, which is 25.90% down from last year.
  • Abeona Therapeutics' Operating Leases amounted to $4.3 million in Q3 2025, which was up 6.94% from $4.0 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Operating Leases high stood at $9.1 million for Q1 2022, and its period low was $3.0 million during Q2 2024.
  • Moreover, its 3-year median value for Operating Leases was $4.0 million (2024), whereas its average is $4.3 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Operating Leases surged by 86.72% in 2022, and later tumbled by 51.25% in 2023.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Operating Leases stood at $7.6 million in 2021, then dropped by 22.57% to $5.9 million in 2022, then fell by 24.80% to $4.4 million in 2023, then decreased by 25.90% to $3.3 million in 2024, then increased by 25.04% to $4.3 million in 2025.
  • Its Operating Leases was $4.3 million in Q3 2025, compared to $4.0 million in Q2 2025 and $4.1 million in Q1 2025.